home > news > detailed info

Change of Company Name: VTU Technology is now VALIDOGEN



VTU Technology GmbH, a leading, globally acting Austrian biotech contract research company developing microbial strains and processes for the production of recombinant proteins, announced today the change of its company name to VALIDOGEN GmbH following a reorganization of VTU Holding GmbH.

Founded in 2008, VTU Technology has become a recognized player in the field of Pichia pastoris based protein production and will now continue its business as VALIDOGEN, a private company and independent subsidiary of KonValue Group. „VALIDOGEN will continue to be a leading partner for the development of microbial protein production strains and processes“, said Dr. Michael Koncar, founder and CEO of VALIDOGEN and KonValue Group.

UNLOCK PICHIA – a technology from VALIDOGEN

In connection with the company’s name change, VALIDOGEN introduces UNLOCK PICHIA as a label for its established, exclusive Pichia protein production technology. UNLOCK PICHIA is known as the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production. The company has been continuously working on the optimization and expansion of its Pichia toolbox, which is unmatched in terms of genetic diversity. UNLOCK PICHIA addresses challenges all the way from transcription and translation to translocation, protein folding and secretion and facilitates the expression of more complex proteins thus maximizing yields without compromising product quality.


VALIDOGEN, a leading contract research and development company, offers the broadest toolbox and most versatile technology platform available for Pichia pastoris recombinant protein production known as UNLOCK PICHIA. VALIDOGEN develops high performance expression strains and economically viable protein production processes for the manufacture of biopharmaceuticals, enzymes and various other recombinant proteins and provides tailormade solutions for customers from different industry sectors – such as pharma, diagnostics, food & feed, chemical, agro and other industries. VALIDOGEN will be a private company and independent subsidiary of KonValue Group.

Dr. Thomas Purkarthofer
Head of Business Development
Parkring 18, A-8074 Raaba-Grambach
Tel: +43 316 4009 4017
phone +43 316 4009 4000
email VALIDOGEN GmbH, Parkring 18, 8074 Raaba-Grambach
Print this page
Send to a friend
News and Press Releases

Envigo launches PATHWAY an optimized safety assessment solution to enable first in human clinical trials

11 March 2019, East Millstone, N.J. – Envigo, a leading provider of non-clinical contract research services and research models, announced today the launch of PATHWAY – an integrated solution that optimizes non-clinical safety assessment programs to enable first-in-human clinical trials. PATHWAY is designed to manage the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers by integrating safety assessment study types and bioanalytical support with scientific and regulatory consulting, program design and project management.
More info >>

White Papers

Industry Events

SMi Presents the 11th Adaptive Designs in Clinical Trials Conference 2019

1-2 April 2019, Holiday Inn Kensington Forum, London

SMi Group are proud to announce the 11th annual Adaptive Designs in Clinical Trials conference and exhibition will return to London from the 1st – 2nd April 2019. With the growing popularity in use and acceptance of adaptive designs in clinical trials - demonstrated most recently with the new FDA draft guidance on adaptive designs – there is a pressing need for a forum which explores this increasingly normalized medical methodology.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement